Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus exemestane biomarker study in advanced hormone receptor-positive breast cancer
NL-OMON21846Recruiting
- Sponsor
- VU University Medical Center
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of everolimus and exemestane in breast cancer, sponsored by VU University Medical Center. Primary endpoints: Biomarker evaluation from primary tumor tissue, new tumor biopsies and blood samples and Progression-free survival. Started Mar 2014; status: recruiting.
02
Drugs
everolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON21846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21846.